Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 50

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 50
---
 the primary offering, resulting in potential depreciation in the value of the shares purchased by investors in the primary offering, and/or significant volatility in the trading price of our shares.

The per Unit public offering price to be sold
by the Company is expected to be $3.20 per Unit. The per share public price of the shares to be sold by the Selling Shareholders following
the quotation of our Common Stock on the OTCQX or the OTCQB marketplace of OTC Market or until the shares of our Common Stock are listed
on a national securities exchange will be at the then-prevailing market price. As a result, purchasers of shares from the Selling
Shareholders could pay more or less per share than investors in our best efforts offering who will have purchased Units at a fixed price.
In addition, rapid market sales or sales in significant volumes of the shares by the Selling Shareholders may significantly dilute the
value of our common stock held by investors in our primary offering, resulting in depreciation of the value of shares purchased at a
fixed price per Unit paid by investors in the primary offering and/or significant volatility in the price of our shares.

<div align='center'>26</div>

Until such time as the shares of Common Stock are quoted on the OTCQX or the OTCQB marketplace of OTC Market or are listed on a national securities exchange, the concurrent offering by the Selling Stockholders in the resale offering may adversely affect the success of our Primary Offering.

We anticipate that the selling shareholders resale
offering will be concurrently conducted when our primary offering of units is still ongoing. The concurrent resale offering by the Selling
stockholders at a fixed per share price of $1.00 until such time as our Common Stock is quoted on the OTCQX or the OTCQB marketplace
or until the shares of our Common Stock are listed on a national securities exchange can adversely affect our ability to raise capital
in the primary offering as the fixed resale price of $1.00 per share can be deemed by prospective investors as more attractive than the
$3.20 price per unit in the primary offering, which can adversely affect the success of our primary offering. In the event that for whatever
reason our Common Stock is not upgraded to the OTCQB or OTCQX tier of OTC Marketplace, of which no assurance can be provided, then we
believe the concurrent offering by the Selling Stockholders may adversely affect the primary offering.

The sale of shares of our Common Stock by Selling Stockholders